⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMY News
Bristol-Myers Squibb Co.
Impact Podcast with John Shegerian Announces All-Star Roster for New Season
businesswire.com
CROX
AMZN
MSFT
V
ZM
CBRE
HPQ
IBM
UBER
PEP
AVD
NU
TD
UPS
CRM
FTI
AMGN
HON
KHC
MAR
MORN
FDX
HTHT
LVS
SCL
SNA
WMT
XOM
GE
JNJ
KO
PG
TGT
DIS
MCD
SBUX
BA
CAT
DD
EMR
LMT
MMM
NEE
RTX
UNH
XRAY
ZTS
AMAT
ADSK
BIIB
BMY
CDNS
CHKP
CTAS
CTSH
DLTR
EA
EXPE
FAST
FIS
GILD
GOOG
HAS
HPE
INTC
INTU
ISRG
JD
LRCX
LIN
LULU
LYFT
MDLZ
MNST
MRNA
MU
NFLX
NVDA
ORCL
PAYX
PDD
PFE
PLTR
PPC
QCOM
REGN
ROST
SIRI
SNPS
SWKS
SYK
TCOM
TEAM
TER
TFX
TXN
ULTA
VRSK
VRTX
WDC
WEC
WST
WYNN
XEL
ZBRA
SAN
Cancer Stress Protein Helps Tumors Hide From Immunity
prnewswire.com
PFE
BMY
KYMR
AGIO
BDTX
PRTA
CAR T - Cell Therapy Competitive Landscape Research Report 2026: Comprehensive Insights About 250+ Companies and 500+ Drugs - Key Opportunities Lie in Targeting Hematologic Malignancies
globenewswire.com
BMY
AUTL
SANA
Monoclonal Antibodies Competitive Landscape Report 2026: Comprehensive Insights About 180+ Companies and 230+ Drugs by Company, Product, Stage of Development, Route of Administration, Molecule Type
globenewswire.com
BMY
GSK
NVS
NVO
Molecular Glues Competitive Landscape Research Report 2026: Comprehensive Insights About 80+ Companies and 90+ Drugs
globenewswire.com
BMY
RVMD
NRIX
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development
businesswire.com
AZN
BMY
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development
businesswire.com
AZN
BMY
Stem Cell Therapy Market to Reach USD 45.2B by 2036 (8.4% CAGR) | U.S., Germany & Japan Lead Growth | Mesenchymal Stem Cells Hold 45% Share -- Future Market Insights
prnewswire.com
MESO
GERN
BCDA
NVS
BMY
Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
prnewswire.com
BMY
ABBV
REGN
LLY
PFE
RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%
globenewswire.com
BMY
AMRN